Research ArticleClinical Studies
Open Access

Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial

MOLLY K. TATE, MIKE HERNANDEZ, JOE Y. CHANG, STEVEN H. LIN, ZHONGXING LIAO, SUJA M. KOSHY, HEATH D. SKINNER and STEPHEN G. CHUN
Anticancer Research January 2024, 44 (1) 133-137; DOI: https://doi.org/10.21873/anticanres.16795

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Phase II clinical trial timeline. SBRT: Stereotactic body radiotherapy; PET: positron emission tomography; CT: computed tomography.

  • Figure 2.
    Figure 2.

    Phase II clinical trial results for all participants. A) Kaplan–Meier analysis of progression-free survival (PFS). B) Kaplan–Meier analysis of overall survival (OS). NA: Not applicable; CI: confidence interval.

  • Figure 3.
    Figure 3.

    Phase II clinical trial results according to randomization arms (metformin versus placebo). A) Kaplan–Meier analysis of progression-free survival. B) Kaplan–Meier analysis of overall survival. CI: Confidence interval.

Tables

  • Table I.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial
MOLLY K. TATE, MIKE HERNANDEZ, JOE Y. CHANG, STEVEN H. LIN, ZHONGXING LIAO, SUJA M. KOSHY, HEATH D. SKINNER, STEPHEN G. CHUN
Anticancer Research Jan 2024, 44 (1) 133-137; DOI: 10.21873/anticanres.16795
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords